Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222

Letter Hematology

Distinct neutralization profile of spike variants by antibodies induced upon SARS-CoV-2 infection or vaccination

Margherita Rosati et al.

AMERICAN JOURNAL OF HEMATOLOGY (2022)

Review Infectious Diseases

Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review

Thibault Fiolet et al.

Summary: Overall, COVID-19 vaccines have high efficacy against the original strain and variants of concern, with rare serious adverse events. However, prices vary significantly for different vaccines.

CLINICAL MICROBIOLOGY AND INFECTION (2022)

添加到收藏夹

Article Immunology

Immune Responses to the ChAdOx1 nCoV-19 and BNT162b2 Vaccines and to Natural Coronavirus Disease 2019 Infections Over a 3-Month Period

Ji Yeun Kim et al.

Summary: The antibody responses induced by BNT162b2 vaccine were higher than those induced by ChAdOx1 vaccine and similar to responses to natural infections. T-cell responses were maintained longer in BNT162b2 vaccinees.

JOURNAL OF INFECTIOUS DISEASES (2022)

添加到收藏夹

Letter Medicine, General & Internal

Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection

Ital Nemet et al.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

News Item Medicine, General & Internal

Covid-19: Fourth vaccine doses-who needs them and why?

Gareth Iacobucci

BMJ-BRITISH MEDICAL JOURNAL (2022)

添加到收藏夹

Article Immunology

Effectiveness of mRNA BNT162b2 Vaccine 6 Months after Vaccination among Patients in Large Health Maintenance Organization, Israel

Jennifer Kertes et al.

Summary: Based on data from a large health maintenance organization in Israel, our analysis found that IgG levels decrease over time in fully vaccinated individuals, and there is an inverse relationship between IgG titer and subsequent PCR-confirmed infection. Early vaccinated individuals during the vaccination campaign were more likely to become infected, and those aged 60 and above had lower initial IgG levels and were at higher risk for infection.

EMERGING INFECTIOUS DISEASES (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

COVID-19-neutralizing antibodies predict disease severity and survival

Wilfredo F. Garcia-Beltran et al.

Summary: Severe cases of COVID-19 show increased inflammatory markers, lymphopenia, pro-inflammatory cytokines, and high antibody levels. High neutralization potency is a predictor of survival. Patient sera can neutralize different strains, indicating cross-protection from reinfection.

CELL (2021)

添加到收藏夹

Article Medicine, General & Internal

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Merryn Voysey et al.

Summary: The ChAdOx1 nCoV-19 vaccine has been shown to have an acceptable safety profile and effectiveness against symptomatic COVID-19, with higher efficacy observed in the group that received a low dose followed by a standard dose.

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

Alasdair P S Munro et al.

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study

Sara Y. Tartof et al.

Summary: This study aimed to assess the overall and variant-specific effectiveness of the BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19-related hospital admissions among members of a healthcare system in California. The effectiveness of the vaccine remained high against hospital admissions even up to 6 months after full vaccination, despite a decline in effectiveness against SARS-CoV-2 infections over time, which was likely due to waning immunity rather than the delta variant escaping vaccine protection.

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal

Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study

Noam Barda et al.

Summary: A study using data from Israel's largest health-care organization showed that a third dose of the BNT162b2 mRNA vaccine is effective in preventing individuals from severe COVID-19-related outcomes, compared to receiving only two doses at least 5 months ago. The effectiveness of the third dose in preventing hospital admission was 93%, severe disease 92%, and COVID-19-related death 81%.

LANCET (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2

Matan Levine-Tiefenbrun et al.

Summary: The study found that the effectiveness of the BNT162b2 vaccine in reducing viral loads of breakthrough infections decreases over time. However, this reduction in viral load can be restored by receiving a third vaccine dose.

NATURE MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Waning Immunity after the BNT162b2 Vaccine in Israel

Yair Goldberg et al.

Summary: The immunity against the delta variant of SARS-CoV-2 waned in all age groups in Israel a few months after receiving the second dose of the vaccine, leading to an increase in infection and severe cases.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

BNT162b2 Vaccine Booster and Mortality Due to Covid-19

Ronen Arbel et al.

Summary: Among 843,208 participants in Israel aged 50 years or older who had received two doses of the BNT162b2 vaccine at least 5 months earlier, those who received a booster had 90% lower mortality due to Covid-19 than those who did not receive a booster during the 54-day study period.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months

Einav G. Levin et al.

Summary: A study in Israel revealed that waning immunity after receiving two doses of the BNT162b2 vaccine led to an increase in the incidence of SARS-CoV-2 infection. Levels of spike-binding IgG and neutralizing antibodies decreased more significantly in men, individuals aged 65 or older, and immunosuppressed individuals in a longitudinal study involving nearly 4000 healthcare workers.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar

Hiam Chemaitelly et al.

Summary: In a study conducted in Qatar involving over 900,000 participants, vaccine effectiveness peaked at 77.5% in the first month after the second dose. However, it declined afterwards to as low as 20% in months 5 through 7 after vaccination, while protection against severe Covid-19 remained above 90% for at least 6 months.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Merryn Voysey et al.

Summary: The AZD1222 vaccine has been approved for emergency use in the UK with an interval of 4-12 weeks between doses. Analysis shows that the vaccine is efficacious with two doses and provides immunoprotection after the first dose before the second dose is administered.

LANCET (2021)

添加到收藏夹

Article Multidisciplinary Sciences

mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern

Rishi R. Goel et al.

Summary: This study found that immune memory to SARS-CoV-2 and its variants remains robust for at least 6 months after mRNA vaccination, with antibodies declining but still detectable in most individuals. mRNA vaccines also induced functional memory B cells and antigen-specific T cells, with recall responses primarily increasing antibody levels in individuals with preexisting immunity.

SCIENCE (2021)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Exploring the COVID-19 vaccine candidates against SARS-CoV-2 and its variants: where do we stand and where do we go?

Gaurav Joshi et al.

Summary: According to WHO, there are 117 COVID-19 vaccines in clinical development and 194 in preclinical development, with major platforms including protein subunit, RNA, and inactivated virus. Despite rapid manufacturing, the wealthiest countries holding only 10.8% of the world population have 28% of total vaccines, indicating an inequity in distribution.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2021)

添加到收藏夹

Article Immunology

Waning of IgG, Total and Neutralizing Antibodies 6 Months Post-Vaccination with BNT162b2 in Healthcare Workers

Jean-Louis Bayart et al.

Summary: Data from this study showed a significant decline in antibodies levels at day 180 post SARS-CoV-2 vaccination, with a more pronounced decrease in neutralizing antibodies. The estimated half-life of IgG was around 21 days in seronegative individuals and 53 days in seropositive individuals, while the half-life of total antibodies ranged from 68 to 114 days. The decline in neutralizing antibodies was particularly stark, with around 45% of subjects testing negative at day 180.

VACCINES (2021)

添加到收藏夹

Article Immunology

BNT162b2 mRNA COVID-19 Vaccine Effectiveness in the Prevention of SARS-CoV-2 Infection and Symptomatic Disease in Five-Month Follow-Up: A Retrospective Cohort Study

Francesco Bianchi et al.

Summary: This study evaluated the effectiveness of the mRNA COVID-19 vaccine among healthcare workers in Italy and found a high efficacy rate against infection and symptomatic diseases. The results suggest the importance of increasing vaccination rates, including mandating vaccinations for healthcare workers and providing more incentives to increase vaccine acceptance among the general population.

VACCINES (2021)

添加到收藏夹

Article Geriatrics & Gerontology

Immunogenicity of the BNT162b2 vaccine in frail or disabled nursing home residents: COVID-A study

Sergio Salmeron Rios et al.

Summary: In a longitudinal cohort study in long-term care facilities in Albacete, Spain, 134 older adults aged >= 65 years received two doses of the BNT162b2 mRNA COVID-19 vaccine, with antibody levels measured 21.9 days after each dose. The vaccine was found to be safe and produced immunogenicity in older adults, regardless of their frailty and disability profiles. Residents with prior COVID-19 infection showed increased antibody levels post-vaccination.

JOURNAL OF THE AMERICAN GERIATRICS SOCIETY (2021)

添加到收藏夹

Article Medicine, General & Internal

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

Eric J. Haas et al.

Summary: This study assessed the real-world effectiveness of the Pfizer-BioNTech mRNA COVID-19 vaccine BNT162b2 in Israel, showing high efficacy in preventing SARS-CoV-2 infections, hospitalizations, severe disease, and death. As vaccine coverage increased, there were marked declines in SARS-CoV-2 outcomes, indicating that COVID-19 vaccination can help control the pandemic.

LANCET (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

David S. Khoury et al.

Summary: The level of neutralizing antibodies is closely related to immune protection against COVID-19, playing a crucial role in protecting against detected infection and severe infection. Studies have shown that neutralizing titers will decline over time after vaccination, leading to decreased protection against SARS-CoV-2 infection.

NATURE MEDICINE (2021)

添加到收藏夹

Article Biology

Robust Neutralizing Antibody Responses 6 Months Post Vaccination with BNT162b2: A Prospective Study in 308 Healthy Individuals

Evangelos Terpos et al.

Summary: The study revealed a persistent but declining humoral immunity against SARS-CoV-2 at six months following full vaccination with BNT162b2 in healthy individuals, with older individuals showing more pronounced decline. About half of the subjects are estimated to have Nabs values below 73.8% and 64.6% at 9 and 12 months post vaccination completion, respectively.

LIFE-BASEL (2021)

添加到收藏夹

Letter Hematology

Comparison of neutralizing antibody responses against SARS-CoV-2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: Should the second AZD1222 vaccine dose be given earlier?

Evangelos Terpos et al.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

添加到收藏夹

Article Infectious Diseases

Effectiveness of mRNA-BNT162b2, mRNA-1273, and ChAdOx1 nCoV-19 vaccines against COVID-19 in healthcare workers: an observational study using surveillance data

Christophe Paris et al.

Summary: The study aimed to estimate the protective efficacy of the first three COVID-19 vaccines available in Western Europe among healthcare workers, and found that the observed effectiveness of these vaccines in HCWs was in line with the efficacy reported in pivotal randomized trials.

CLINICAL MICROBIOLOGY AND INFECTION (2021)

添加到收藏夹

Letter Medicine, General & Internal

Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination

Emma C. Wall et al.

LANCET (2021)

添加到收藏夹

Editorial Material Infectious Diseases

COVID-19 vaccine equity and booster doses

LANCET INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Medicine, General & Internal

Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel

Yinon M. Bar-On et al.

Summary: After receiving a third dose of the BNT162b2 mRNA vaccine, Israeli residents aged 60 and above who had previously received two doses of the vaccine saw significantly lower rates of confirmed Covid-19 infection and severe illness compared to those who did not receive a booster shot, indicating the effectiveness of the booster dose in reducing infection and severe illness.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months

S. J. Thomas et al.

Summary: BNT162b2 vaccine remains highly effective and safe over the course of 6 months post-vaccination, with efficacy rates ranging from 86% to 100% across different demographics and risk factors for Covid-19. The vaccine also shows a high efficacy against severe disease, with particularly promising results observed in South Africa against the B.1.351 variant.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants

Pinja Jalkanen et al.

Summary: The study shows that the second dose of the BNT162b2 vaccine can induce cross-neutralization to some extent of SARS-CoV-2 variants, providing partial protection. Despite the reduced neutralization effect on the B.1.351 variant, the majority of vaccinees still have some level of protection.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Cell Biology

Kinetics of Anti-SARS-CoV-2 Antibody Responses 3 Months Post Complete Vaccination with BNT162b2; A Prospective Study in 283 Health Workers

Evangelos Terpos et al.

Summary: The study revealed that there was a persistent but declining trend in neutralizing antibodies and anti-S-RBD IgG levels up to 3 months after full vaccination with the BNT162b2 mRNA vaccine. Prior COVID-19 infection and younger age were associated with stronger antibody responses over time.

CELLS (2021)

添加到收藏夹

Article Health Care Sciences & Services

Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study

Paul Naaber et al.

Summary: The study found that antibody levels declined at 12 weeks and 6 months after receiving two doses of BNT162b2 vaccine, with Spike antibody levels at 6 months being similar to those in individuals who received one dose or had recovered from COVID-19. Most individuals developed Spike-specific memory T cell responses, which were lower in those with higher T cell immunosenescence. Antibody response was negatively correlated with age and positively correlated with the total score of vaccination side effects.

LANCET REGIONAL HEALTH-EUROPE (2021)

添加到收藏夹

Article Immunology

Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape

John S. Tregoning et al.

Summary: The development and rollout of vaccines have brought hope for controlling the COVID-19 pandemic, with vaccines proving highly effective in preventing disease. However, challenges remain in ensuring equitable access to vaccines globally, as well as lessons to be learned for controlling pandemics in the future.

NATURE REVIEWS IMMUNOLOGY (2021)

添加到收藏夹

Article Multidisciplinary Sciences